Large-particle calcium hydroxylapatite injection for correction of facial wrinkles and depressions

Murad Alam*, Jillian Havey, Natalie Pace, Marisa Pongprutthipan, Simon S Yoo

*Corresponding author for this work

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Small-particle calcium hydroxylapatite (Radiesse, Merz, Frankfurt, Germany) is safe and effective for facial wrinkle reduction, and has medium-term persistence for this indication. There is patient demand for similar fillers that may be longer lasting. Objective: We sought to assess the safety and persistence of effect in vivo associated with use of large-particle calcium hydroxylapatite (Coaptite, Merz) for facial augmentation and wrinkle reduction. Methods: This was a case series of 3 patients injected with large-particle calcium hydroxylapatite. Results: Large-particle calcium hydroxylapatite appears to be effective and well tolerated for correction of facial depressions, including upper mid-cheek atrophy, nasolabial creases, and HIV-associated lipoatrophy. Adverse events included erythema and edema, and transient visibility of the injection sites. Treated patients, all of whom had received small-particle calcium hydroxylapatite correction before, noted improved persistence at 6 and 15 months with the large-particle injections as compared with prior small-particle injections. Limitations: This is a small case series, and there was no direct control to compare the persistence of small-particle versus large-particle correction. Conclusions: For facial wrinkle correction, large-particle calcium hydroxylapatite has a safety profile comparable with that of small-particle calcium hydroxylapatite. The large-particle variant may have longer persistence that may be useful in selected clinical circumstances.

Original languageEnglish (US)
Pages (from-to)92-96
Number of pages5
JournalJournal of the American Academy of Dermatology
Volume65
Issue number1
DOIs
StatePublished - Jul 1 2011

Fingerprint

Durapatite
Calcium
Injections
Safety
Cheek
Erythema
Atrophy
Germany
Edema
HIV

Keywords

  • Coaptite
  • HIV lipoatrophy
  • calcium hydroxylapatite
  • cheek augmentation
  • facial augmentation
  • fillers
  • soft-tissue augmentation
  • wrinkle reduction

ASJC Scopus subject areas

  • Dermatology

Cite this

@article{8a680d7eb1064ad68b9a04b1806fca68,
title = "Large-particle calcium hydroxylapatite injection for correction of facial wrinkles and depressions",
abstract = "Background: Small-particle calcium hydroxylapatite (Radiesse, Merz, Frankfurt, Germany) is safe and effective for facial wrinkle reduction, and has medium-term persistence for this indication. There is patient demand for similar fillers that may be longer lasting. Objective: We sought to assess the safety and persistence of effect in vivo associated with use of large-particle calcium hydroxylapatite (Coaptite, Merz) for facial augmentation and wrinkle reduction. Methods: This was a case series of 3 patients injected with large-particle calcium hydroxylapatite. Results: Large-particle calcium hydroxylapatite appears to be effective and well tolerated for correction of facial depressions, including upper mid-cheek atrophy, nasolabial creases, and HIV-associated lipoatrophy. Adverse events included erythema and edema, and transient visibility of the injection sites. Treated patients, all of whom had received small-particle calcium hydroxylapatite correction before, noted improved persistence at 6 and 15 months with the large-particle injections as compared with prior small-particle injections. Limitations: This is a small case series, and there was no direct control to compare the persistence of small-particle versus large-particle correction. Conclusions: For facial wrinkle correction, large-particle calcium hydroxylapatite has a safety profile comparable with that of small-particle calcium hydroxylapatite. The large-particle variant may have longer persistence that may be useful in selected clinical circumstances.",
keywords = "Coaptite, HIV lipoatrophy, calcium hydroxylapatite, cheek augmentation, facial augmentation, fillers, soft-tissue augmentation, wrinkle reduction",
author = "Murad Alam and Jillian Havey and Natalie Pace and Marisa Pongprutthipan and Yoo, {Simon S}",
year = "2011",
month = "7",
day = "1",
doi = "10.1016/j.jaad.2010.12.018",
language = "English (US)",
volume = "65",
pages = "92--96",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "1",

}

Large-particle calcium hydroxylapatite injection for correction of facial wrinkles and depressions. / Alam, Murad; Havey, Jillian; Pace, Natalie; Pongprutthipan, Marisa; Yoo, Simon S.

In: Journal of the American Academy of Dermatology, Vol. 65, No. 1, 01.07.2011, p. 92-96.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Large-particle calcium hydroxylapatite injection for correction of facial wrinkles and depressions

AU - Alam, Murad

AU - Havey, Jillian

AU - Pace, Natalie

AU - Pongprutthipan, Marisa

AU - Yoo, Simon S

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Background: Small-particle calcium hydroxylapatite (Radiesse, Merz, Frankfurt, Germany) is safe and effective for facial wrinkle reduction, and has medium-term persistence for this indication. There is patient demand for similar fillers that may be longer lasting. Objective: We sought to assess the safety and persistence of effect in vivo associated with use of large-particle calcium hydroxylapatite (Coaptite, Merz) for facial augmentation and wrinkle reduction. Methods: This was a case series of 3 patients injected with large-particle calcium hydroxylapatite. Results: Large-particle calcium hydroxylapatite appears to be effective and well tolerated for correction of facial depressions, including upper mid-cheek atrophy, nasolabial creases, and HIV-associated lipoatrophy. Adverse events included erythema and edema, and transient visibility of the injection sites. Treated patients, all of whom had received small-particle calcium hydroxylapatite correction before, noted improved persistence at 6 and 15 months with the large-particle injections as compared with prior small-particle injections. Limitations: This is a small case series, and there was no direct control to compare the persistence of small-particle versus large-particle correction. Conclusions: For facial wrinkle correction, large-particle calcium hydroxylapatite has a safety profile comparable with that of small-particle calcium hydroxylapatite. The large-particle variant may have longer persistence that may be useful in selected clinical circumstances.

AB - Background: Small-particle calcium hydroxylapatite (Radiesse, Merz, Frankfurt, Germany) is safe and effective for facial wrinkle reduction, and has medium-term persistence for this indication. There is patient demand for similar fillers that may be longer lasting. Objective: We sought to assess the safety and persistence of effect in vivo associated with use of large-particle calcium hydroxylapatite (Coaptite, Merz) for facial augmentation and wrinkle reduction. Methods: This was a case series of 3 patients injected with large-particle calcium hydroxylapatite. Results: Large-particle calcium hydroxylapatite appears to be effective and well tolerated for correction of facial depressions, including upper mid-cheek atrophy, nasolabial creases, and HIV-associated lipoatrophy. Adverse events included erythema and edema, and transient visibility of the injection sites. Treated patients, all of whom had received small-particle calcium hydroxylapatite correction before, noted improved persistence at 6 and 15 months with the large-particle injections as compared with prior small-particle injections. Limitations: This is a small case series, and there was no direct control to compare the persistence of small-particle versus large-particle correction. Conclusions: For facial wrinkle correction, large-particle calcium hydroxylapatite has a safety profile comparable with that of small-particle calcium hydroxylapatite. The large-particle variant may have longer persistence that may be useful in selected clinical circumstances.

KW - Coaptite

KW - HIV lipoatrophy

KW - calcium hydroxylapatite

KW - cheek augmentation

KW - facial augmentation

KW - fillers

KW - soft-tissue augmentation

KW - wrinkle reduction

UR - http://www.scopus.com/inward/record.url?scp=79958865879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958865879&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2010.12.018

DO - 10.1016/j.jaad.2010.12.018

M3 - Article

VL - 65

SP - 92

EP - 96

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 1

ER -